Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies.
Cosgun KN, Jumaa H, Robinson ME, Kistner KM, Xu L, Xiao G, Chan LN, Lee J, Kume K, Leveille E, Fonseca-Arce D, Khanduja D, Ng HL, Feldhahn N, Song J, Chan WC, Chen J, Taketo MM, Kothari S, Davids MS, Schjerven H, Jellusova J, Müschen M.
Cosgun KN, et al. Among authors: ng hl.
bioRxiv [Preprint]. 2023 Mar 15:2023.03.13.532152. doi: 10.1101/2023.03.13.532152.
bioRxiv. 2023.
PMID: 36993619
Free PMC article.
Preprint.
Clinically approved GSK3beta-inhibitors that achieved favorable safety prof les at micromolar concentrations in clinical trials for neurological disorders and solid tumors were effective at low nanomolar concentrations in B-cell malignancies, induced massive accumulation o …
Clinically approved GSK3beta-inhibitors that achieved favorable safety prof les at micromolar concentrations in clinical trials for n …